HCW Biologics announced settlement and extinguishment of $2.8 million in disputed accounts payable.

Key Highlights:

  • Reached settlement resolving $2.8M of disputed accounts payable during quarter ended June 30, 2026.
  • B&I Contractors filed voluntary dismissal with prejudice and satisfied a $1.1M lien on company property.
  • Paid EirGenix in full under settlement: $620,000 on March 3, 2026 and $620,000 on May 26, 2026, resolving $1.2M agreed amount.
  • Dismissal and lien satisfaction complete settlement with B&I, fully resolving outstanding amounts related to Miramar property renovations.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.